Get the Stockscreener App
7.35
0.81%
-0.06
After Hours:
29.72
22.37
+304.35%
Relmada Therapeutics Inc stock is traded at $7.35, with a volume of 719.36K.
It is down -0.81% in the last 24 hours and up +5.15% over the past month.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
See More
Previous Close:
$7.41
Open:
$7.49
24h Volume:
719.36K
Relative Volume:
0.42
Market Cap:
$770.93M
Revenue:
-
Net Income/Loss:
$-57.39M
P/E Ratio:
-5.0007
EPS:
-1.4698
Net Cash Flow:
$-45.79M
1W Performance:
+1.52%
1M Performance:
+5.15%
6M Performance:
+192.83%
1Y Performance:
+1,818%
1-Day Range:
$7.175
$7.63
1-Week Range:
$7.085
$7.805
52-Week Range:
$0.3233
$7.94
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, GOODO, SHMD, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.485 | 3.18B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.29 | 306.92M | 52.15M | -21.46M | 0 | -0.4675 |
PSNYW
Polestar Automotive Holding Uk
|
3.09 | 271.04M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.06 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
| Jan-23-26 | Resumed | Leerink Partners | Outperform |
| Dec-22-25 | Initiated | Jefferies | Buy |
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - Investing News Network
Bladder cancer drug NDV-01 heads to AUA with Phase 3 on track - Stock Titan
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - GlobeNewswire Inc.
Commodore holds 5.5M RLMD shares, including 4.21M warrant shares (RLMD) - Stock Titan
Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect? - MSN
Relmada Therapeutics (RLMD) Stock Chart | Relmada Therapeutics Inc. posts 103% EPS miss vs estimatesReal Trader Network - UBND thành phố Hải Phòng
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - qz.com
Relmada Therapeutics Inc erwartet einen Verlust von 70 Cents pro AktieEarnings Preview - TradingView
Relmada Therapeutics (RLMD) Stock: Solid Choice? (Breakout Watch) 2026-04-20Investment Picks - Xã Vĩnh Công
Relmada (NASDAQ: RLMD) details 2025 turnaround, seeks share and plan increases - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3%Here's What Happened - MarketBeat
Relmada Therapeutics shares jump 25% after promising bladder cancer trial results - MSN
Q3 2025 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat
Form PRE 14AOther preliminary proxy statements - ADVFN
[EFFECT] RELMADA THERAPEUTICS, INC. SEC Filing - Stock Titan
Shorts Report: Is Relmada Therapeutics Inc a speculative investmentGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale under 424B3 - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Hits New 12-Month HighShould You Buy? - MarketBeat
Aug Update: Should I invest in Relmada Therapeutics Inc before earningsM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
Volume Recap: Does Relmada Therapeutics Inc offer margin of safety2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Report: Whats next for Relmada Therapeutics Inc stock2026 WrapUp & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Mizuho reiterates Relmada stock rating on Phase 3 trial progress By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating on Phase 3 trial progress - Investing.com UK
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD) - The Globe and Mail
Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - Stock Titan
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
Can Relmada Therapeutics (RLMD) Stock Go Higher | Price at $6.94, Down 0.72%Investment Signal Network - Cổng thông tin điện tử Tỉnh Sơn La
RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RLMD PE Ratio & Valuation, Is RLMD Overvalued - Intellectia AI
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - Stock Titan
RLMD Stock Analysis: Relmada Therapeutics Inc slips 1.55% to $6.99 in biotech trading - UBND thành phố Hải Phòng
Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - Yahoo Finance UK
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength - The Globe and Mail
RLMD Stock Surges 42% in a Week: Here's What You Should Know - Eastern Progress
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - Stock Titan
Relmada wins bullish view at Piper Sandler on cancer therapy - MSN
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):